Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash, securing a CLIA/CAP lab and SomaScan proteomics capabilities. The deal brings Krex antibody profiling technology and a path to integrate SomaMer/Protein Prep assays with Illumina’s NGS and DRAGEN ecosystems. Illumina said it will maintain Boulder operations and leverage combined platforms to expand high‑throughput proteomics and multiomics products. The transaction strengthens Illumina’s commercial footprint in protein measurement and clinical‑grade proteomics workflows.